Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug649 | Brief Behavioral Activation with Mental Imagery Wiki | 1.00 |
| drug4698 | recovered covid 19 patients plasma Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This research study is designed to investigate the effects of a brief psychological intervention for improving depressed mood in older individuals (65 years and older) in isolation during the Coronavirus (COVID-19) pandemic. The treatment is delivered by telephone and consists of four weekly individual sessions. Two therapeutic methods are used in combination during this intervention: Behavioral activation (BA) and Mental Imagery (MI). BA involves identifying and scheduling enjoyable and meaningful activities to improve mood and reduce social isolation. To enhance BA efficacy and adherence, MI is paired with BA as MI is known to activate emotion and motivation. The MI intervention in this study involves having participants imagine, in vivid sensory detail, engaging in some of the activities that are scheduled during BA. Approximately 154 individuals will participate in the study. Half of the participants will be randomised to start the intervention immediately, while the other half of the participants will be randomized to a control group receiving the intervention after 4 weeks. This procedure makes it possible to evaluate the effects of the treatment while not disadvantaging participants randomized to the control group. Participants will be asked to fill in questionnaires before, during (at the end of each intervention week), and after treatment (or waiting period for the control group). Questionnaires will also be sent 1-, 3- and 6 months after treatment to follow up on the results. A smaller group of participants (10-15) will be asked to participate in a more detailed interview about how they experienced the treatment.
Description: MADRS-S is a nine-item questionnaire used to measure severity of depression. The score ranges from 0-54.
Measure: Change from baseline in depressive symptoms using the Montgomery-Asberg Depression Rating Scale, MADRS-S Time: Baseline; Intervention Week 1; Intervention Week 2; Intervention Week 3; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.Description: GDS-15 is a 15-item questionnaire used to identify depression in the elderly. The score ranges from 0-15.
Measure: Change from baseline in depressive symptoms using the Geriatric Depression Rating Scale 15, GDS-15 Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.Description: PHQ-9 is a nine-item questionnaire used to identify depression as well as measuring severity of depression. The score ranges from 0-27.
Measure: Change from baseline in depressive symptoms using the Patient Health Questionnaire 9, PHQ-9 Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.Description: MINI is a structured clinical interview used to assess the presence/absence of common psychiatric disorders.
Measure: Change in depression diagnosis assessed using the Mini International Neuropsychiatric Interview, MINI Time: Baseline; Intervention Week 4.Description: GAD-7 is a seven-item questionnaire used to identify generalized anxiety disorder as well as measuring severity of anxiety symptoms. The score ranges from 0-21.
Measure: Change from baseline in anxiety symptoms using the Generalized Anxiety Disorder 7-item, GAD-7 Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.Description: BADS-SF is a nine-item questionnaire used to measure changes in avoidance and activation. The score ranges from 0-54.
Measure: Change from baseline in behavioral activation using The Behavioral Activation for Depression Scale - Short Form, BADS-SF Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.Description: WHODAS-12 is a 12-item questionnaire used to assess disability due to health conditions. The total score ranges from 0-48.
Measure: Change from baseline in health and disability using The WHO Disability Assessment Schedule 12-item, WHODAS Time: Baseline; Intervention Week 4; 1 month post-intervention; 3 months post-intervention; 6 months post-intervention.Description: NEQ is a 20-item questionnaire used to assess adverse and unwanted effects of psychological treatments.
Measure: Adverse and unwanted effects of the experimental intervention using the Negative Effects Questionnaire, NEQ Time: Experimental Intervention Week 4.Description: Psi-Q is a 35-item questionnaire assessing the vividness of mental imagery. In this study we plan to use the visual subscale with five items, with a total score ranging from 0-50.
Measure: Mental imagery is assessed at baseline using the Plymouth Sensory Imagery Questionnaire, Psi-Q Time: Baseline; Intervention Week 4.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports